Lantheus Announces Collaboration To Provide Novel Tau Imaging Agent For Large Consortium Clinical Trial Sponsored By The National Institute On Aging
Portfolio Pulse from Benzinga Newsdesk
Lantheus Holdings, Inc. (NASDAQ:LNTH) has entered into a collaboration with the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) study, sponsored by the National Institute on Aging, to supply MK-6240, a clinical-stage PET imaging agent targeting tau tangles in Alzheimer's disease research. The CLARiTI study, involving all 37 Alzheimer's Disease Research Centers in the U.S., aims to recruit 2,000 subjects to advance understanding and treatment of dementia.
February 13, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lantheus Holdings, Inc. collaborates with the CLARiTI study to supply MK-6240, a PET imaging agent for Alzheimer's research, potentially advancing the understanding and treatment of dementia.
The collaboration with the CLARiTI study positions Lantheus at the forefront of Alzheimer's research, potentially enhancing its reputation and opening up future revenue streams from MK-6240 if the study yields positive results. This strategic move could positively impact investor sentiment and Lantheus' stock price in the short term, as it highlights the company's active role in addressing a major healthcare challenge.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90